Kazia Therapeutics (Kazia Therapeutics) Total Liabilities : $10.76 Mil (As of Jun. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics Total Liabilities?

Kazia Therapeutics's Total Liabilities for the quarter that ended in Jun. 2023 was $10.76 Mil.

Kazia Therapeutics's quarterly Total Liabilities declined from Jun. 2022 ($12.38 Mil) to Dec. 2022 ($10.97 Mil) and declined from Dec. 2022 ($10.97 Mil) to Jun. 2023 ($10.76 Mil).

Kazia Therapeutics's annual Total Liabilities declined from Jun. 2021 ($14.71 Mil) to Jun. 2022 ($12.38 Mil) and declined from Jun. 2022 ($12.38 Mil) to Jun. 2023 ($10.76 Mil).

Kazia Therapeutics Total Liabilities Historical Data

The historical data trend for Kazia Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Total Liabilities Chart

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

4.85

6.17

14.71

12.38

10.76

Kazia Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Liabilities	Get a 7-Day Free Trial															14.71	13.72	12.38	10.97	10.76

Kazia Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kazia Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.077	+	(0	+	4.108
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1.536	+	0.04)
	=	10.76

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	18.848	-	8.087
	=	10.76

Kazia Therapeutics's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.077	+	(0	+	4.108
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1.536	+	0.04)
	=	10.76

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	18.848	-	8.087
	=	10.76

Kazia Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204